New Service: Alicanto for Antibody Discovery from Human Serum
We recently had the pleasure of attending the PEGS Boston Conference. We had the privilege of showcasing our work through a poster presentation, a talk, and an exhibit booth. Among the highlights were engaging with experts, exchanging ideas, and strengthening our network within the community. But perhaps the most important was launching our newest service: Alicanto For Antibody Discovery From Human Serum. It was truly a great time for Abterra Biosciences!
Watch our CEO, Dr. Natalie Castellana’s presentation on Discovering SARS-CoV2 Antibodies From Patient Serum With Alicanto below. This was our first antibody discovery project utilizing human serum!
Click below to watch the presentation.
Related Posts
Antibody Clonality Assessment
Antibody Clonality Background The serological compartment is simple to access and contains a multitude of proteins, a large fraction of which are circulating antibodies. At Abterra Bio, we developed Alicanto which utilizes B cells from a variety of sources, including...
Unlocking the Secrets of SARS-CoV-2 Immunity: A Deep Dive into Serum Antibodies and B Cell Repertoires
Project Summary We're excited to share our latest findings on the complex interplay between serum antibodies and B cell repertoires in individuals with SARS-CoV-2 immunity. Our study offers new insights into the development of high-affinity antibodies against emerging...
VHH Discovery with Alicanto versus Phage Display
Project Summary Camelids such as llamas and alpacas produce conventional antibodies as well as heavy-chain only antibodies (HCAbs) from which the small, stable, antigen-binding domain (VHH) can be extracted. Target-specific VHHs can be identified from immunized...
Get In Touch